WKP|Q121456772

Search

Select Field:

Select Index:

Search Terms:

Leader		00000nz a2200037n 45 0
001		WKP\|Q121456772 (VIAF cluster) (Authority/Source Record)
003		WKP
005		20241221010805.0
008		241221nneanz\|\|abbn n and d
035		‎‡a (WKP)Q121456772‏
035		‎‡a (OCoLC)Q121456772‏
100	0	‎‡a Mary Beth Serrano‏ ‎‡c researcher‏ ‎‡9 en‏
670		‎‡a Author's A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.‏
670		‎‡a Author's A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder‏
670		‎‡a Author's Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial‏
670		‎‡a Author's Baseline prevalence of Axis I diagnosis in the Ohio Army National Guard‏
670		‎‡a Author's Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder‏
670		‎‡a Author's Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial‏
670		‎‡a Author's Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study‏
670		‎‡a Author's Potentially modifiable pre-, peri-, and postdeployment characteristics associated with deployment-related posttraumatic stress disorder among ohio army national guard soldiers‏
670		‎‡a Author's PTSD comorbidity and suicidal ideation associated with PTSD within the Ohio Army National Guard‏
670		‎‡a Author's Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study‏
670		‎‡a Author's Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity‏
670		‎‡a Author's Validation of lay-administered mental health assessments in a large Army National Guard cohort.‏
919		‎‡a validationoflayadministeredmentalhealthassessmentsinalargearmynationalguardcohort‏ ‎‡A Validation of lay-administered mental health assessments in a large Army National Guard cohort.‏ ‎‡9 1‏
919		‎‡a acuteefficacyofdivalproexsodiumversusplaceboinmoodstabilizernaivebipolar1or2depressionadoubleblindrandomizedplacebocontrolledtrial‏ ‎‡A Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial‏ ‎‡9 1‏
919		‎‡a placebocontrolledstudyofquetiapinexrinbipolardepressionaccompaniedbygeneralizedanxietywithandwithoutarecenthistoryofalcoholandcannabisuse‏ ‎‡A A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.‏ ‎‡9 1‏
919		‎‡a disagreementbetweenselfreportedandclinicianascertainedsuicidalideationanditscorrelationwithdepressionandanxietyseverityinpatientswithmajordepressivedisorderorbipolardisorder‏ ‎‡A Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder‏ ‎‡9 1‏
919		‎‡a baselineprevalenceofaxis1diagnosisintheohioarmynationalguard‏ ‎‡A Baseline prevalence of Axis I diagnosis in the Ohio Army National Guard‏ ‎‡9 1‏
919		‎‡a efficacyandsafetyofquetiapinexrasmonotherapyoradjunctivetherapytoamoodstabilizerinacutebipolardepressionwithgeneralizedanxietydisorderandothercomorbiditiesarandomizedplacebocontrolledtrial‏ ‎‡A Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial‏ ‎‡9 1‏
919		‎‡a lamotrigineadjunctivetherapytolithiumanddivalproexindepressedpatientswithrapidcyclingbipolardisorderandarecentsubstanceusedisordera12weekdoubleblindplacebocontrolledpilotstudy‏ ‎‡A Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study‏ ‎‡9 1‏
919		‎‡a potentiallymodifiablepreperiandpostdeploymentcharacteristicsassociatedwithdeploymentrelatedposttraumaticstressdisorderamongohioarmynationalguardsoldiers‏ ‎‡A Potentially modifiable pre-, peri-, and postdeployment characteristics associated with deployment-related posttraumatic stress disorder among ohio army national guard soldiers‏ ‎‡9 1‏
919		‎‡a ptsdcomorbidityandsuicidalideationassociatedwithptsdwithintheohioarmynationalguard‏ ‎‡A PTSD comorbidity and suicidal ideation associated with PTSD within the Ohio Army National Guard‏ ‎‡9 1‏
919		‎‡a randomizedplacebocontrolledpilotstudyofquetiapinexrmonotherapyoradjunctivetherapytoantidepressantinacutemajordepressivedisorderwithcurrentgeneralizedanxietydisorder‏ ‎‡A A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder‏ ‎‡9 1‏
919		‎‡a safetyandefficacyofolanzapinemonotherapyintreatmentresistantbipolarmaniaa12weekopenlabelstudy‏ ‎‡A Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study‏ ‎‡9 1‏
919		‎‡a shouldanassessmentofaxis1comorbiditybeincludedintheinitialdiagnosticassessmentofmooddisordersroleofqids16srtotalscoreinpredictingnumberofaxis1comorbidity‏ ‎‡A Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity‏ ‎‡9 1‏
996		‎‡2 BNF\|17828398‏
996		‎‡2 ISNI\|0000000371327097‏
996		‎‡2 LC\|n 2011182121‏
996		‎‡2 LC\|n 87877167‏
996		‎‡2 LC\|n 2009024283‏
996		‎‡2 BNE\|XX922193‏
996		‎‡2 SUDOC\|081378149‏
996		‎‡2 BNE\|XX1767950‏
996		‎‡2 ISNI\|0000000035763156‏
996		‎‡2 LC\|no 91017575‏
996		‎‡2 BLBNB\|000261573‏
996		‎‡2 DNB\|12815859X‏
996		‎‡2 LC\|n 2019074233‏
996		‎‡2 BNE\|XX1019243‏
996		‎‡2 PLWABN\|9810559787005606‏
996		‎‡2 SUDOC\|030492246‏
996		‎‡2 SUDOC\|029920884‏
996		‎‡2 SUDOC\|180179799‏
996		‎‡2 RERO\|A000148153‏
996		‎‡2 DNB\|1181875013‏
996		‎‡2 LC\|n 2017181754‏
996		‎‡2 ISNI\|000000011322938X‏
996		‎‡2 BLBNB\|000282785‏
996		‎‡2 LC\|n 97112624‏
996		‎‡2 LC\|n 96028044‏
996		‎‡2 LC\|nb2020000883‏
996		‎‡2 LC\|nr 91002824‏
996		‎‡2 DNB\|1325655384‏
996		‎‡2 BNE\|XX1281977‏
996		‎‡2 BNE\|XX957764‏
996		‎‡2 SUDOC\|196783283‏
996		‎‡2 BNE\|XX5445966‏
996		‎‡2 SUDOC\|191888591‏
996		‎‡2 RERO\|A002955071‏
996		‎‡2 PTBNP\|1584696‏
996		‎‡2 ISNI\|0000000118736321‏
996		‎‡2 LC\|no2001062368‏
996		‎‡2 DNB\|139123326‏
996		‎‡2 BNF\|17708890‏
996		‎‡2 BNC\|981058526950206706‏
996		‎‡2 LIH\|LNB:2N_o_;=BV‏
996		‎‡2 BNE\|XX5656014‏
996		‎‡2 DNB\|1153614820‏
996		‎‡2 LC\|n 85018894‏
996		‎‡2 BNE\|XX5489539‏
996		‎‡2 DNB\|1074669258‏
996		‎‡2 BNF\|17956592‏
996		‎‡2 BNE\|XX4580721‏
996		‎‡2 SUDOC\|111059755‏
996		‎‡2 ISNI\|0000000073317608‏
996		‎‡2 PLWABN\|9810640436705606‏
996		‎‡2 BNF\|14556603‏
996		‎‡2 BNE\|XX1119434‏
996		‎‡2 BNE\|XX1038925‏
996		‎‡2 BNC\|981058511059906706‏
996		‎‡2 NII\|DA0687048X‏
996		‎‡2 LC\|no2017059671‏
996		‎‡2 DNB\|1145334148‏
996		‎‡2 BIBSYS\|98029062‏
996		‎‡2 RERO\|A005838778‏
996		‎‡2 SUDOC\|078644437‏
996		‎‡2 PLWABN\|9810626268505606‏
996		‎‡2 ISNI\|0000000107358708‏
996		‎‡2 BNC\|981058523851806706‏
996		‎‡2 BNE\|XX5469155‏
996		‎‡2 DNB\|140230602‏
996		‎‡2 PTBNP\|1737109‏
996		‎‡2 BNE\|XX6375456‏
996		‎‡2 BNE\|XX1050276‏
996		‎‡2 BNE\|XX5634995‏
996		‎‡2 SUDOC\|08797956X‏
996		‎‡2 BNE\|XX1075523‏
996		‎‡2 LC\|no2016157089‏
996		‎‡2 PLWABN\|9812484101905606‏
996		‎‡2 SUDOC\|033184615‏
996		‎‡2 LC\|n 93065300‏
996		‎‡2 LC\|no2018104874‏
996		‎‡2 LC\|nb2016008039‏
996		‎‡2 ISNI\|0000000499514174‏
996		‎‡2 BNF\|16536544‏
996		‎‡2 BNE\|XX924442‏
996		‎‡2 NII\|DA15449781‏
996		‎‡2 DNB\|1074954955‏
996		‎‡2 NII\|DA07722284‏
996		‎‡2 ISNI\|0000000081319785‏
996		‎‡2 PLWABN\|9810680486705606‏
996		‎‡2 DNB\|1157238270‏
996		‎‡2 ISNI\|0000000123466274‏
996		‎‡2 ISNI\|000000002415702X‏
996		‎‡2 BNF\|16271835‏
996		‎‡2 SUDOC\|172241251‏
996		‎‡2 ISNI\|0000000384966023‏
996		‎‡2 BNE\|XX6471179‏
996		‎‡2 J9U\|987007440804705171‏
996		‎‡2 RERO\|A003823010‏
996		‎‡2 ERRR\|a12233791‏
996		‎‡2 ARBABN\|000058620‏
996		‎‡2 ISNI\|0000000443919359‏
996		‎‡2 PLWABN\|9812830165305606‏
996		‎‡2 BNE\|XX5110015‏
996		‎‡2 BNC\|981058612085806706‏
996		‎‡2 BNCHL\|10000000000000000216269‏
996		‎‡2 PTBNP\|1430002‏
996		‎‡2 BNF\|12189587‏
996		‎‡2 ISNI\|0000000093555232‏
996		‎‡2 BNE\|XX5132226‏
996		‎‡2 NUKAT\|n 98040238‏
996		‎‡2 LNB\|LNC10-000308612‏
996		‎‡2 LC\|n 86052652‏
996		‎‡2 LNB\|LNC10-000308610‏
996		‎‡2 BNF\|12407681‏
996		‎‡2 DNB\|138579369‏
996		‎‡2 J9U\|987007404344705171‏
996		‎‡2 JPG\|500683824‏
996		‎‡2 BNE\|XX4948523‏
996		‎‡2 BNC\|981058613982606706‏
996		‎‡2 CAOONL\|ncf11595419‏
996		‎‡2 BNE\|XX5740265‏
996		‎‡2 SUDOC\|067005926‏
996		‎‡2 ISNI\|0000000059237943‏
996		‎‡2 BNCHL\|10000000000000000139158‏
996		‎‡2 ISNI\|0000000059715255‏
996		‎‡2 ISNI\|0000000373753970‏
996		‎‡2 LC\|no 00064533‏
996		‎‡2 BNE\|XX935037‏
996		‎‡2 LC\|nb2002015795‏
996		‎‡2 LC\|nb2011020220‏
996		‎‡2 LC\|n 83049459‏
996		‎‡2 SUDOC\|031193722‏
996		‎‡2 ISNI\|000000043484974X‏
996		‎‡2 BNE\|XX1470669‏
996		‎‡2 ISNI\|0000000116962990‏
996		‎‡2 J9U\|987007315745105171‏
996		‎‡2 DNB\|1261861949‏
996		‎‡2 DNB\|1059931370‏
996		‎‡2 BNE\|XX1085998‏
996		‎‡2 BNE\|XX1461446‏
996		‎‡2 BNE\|XX930246‏
996		‎‡2 ISNI\|0000000138748899‏
996		‎‡2 NUKAT\|n 2008150252‏
996		‎‡2 BNE\|XX947712‏
996		‎‡2 BNE\|XX6146119‏
996		‎‡2 ISNI\|0000000500039279‏
996		‎‡2 DNB\|133169200‏
996		‎‡2 NYNYRILM\|393332‏
996		‎‡2 BNE\|XX1266130‏
996		‎‡2 LC\|nb2018014633‏
996		‎‡2 LC\|nb 99128031‏
996		‎‡2 RERO\|A023981877‏
996		‎‡2 PTBNP\|78605‏
996		‎‡2 DNB\|129967335‏
996		‎‡2 ISNI\|0000000120745358‏
996		‎‡2 SZ\|171834054‏
996		‎‡2 LC\|no2012128647‏
996		‎‡2 ISNI\|0000000034929169‏
996		‎‡2 PTBNP\|236522‏
996		‎‡2 LC\|n 2001036574‏
996		‎‡2 NSK\|000245137‏
996		‎‡2 DNB\|1056622725‏
996		‎‡2 BNE\|XX1617858‏
996		‎‡2 SUDOC\|077315847‏
996		‎‡2 SUDOC\|185130550‏
996		‎‡2 BNE\|XX992353‏
996		‎‡2 SUDOC\|052532909‏
996		‎‡2 DNB\|1025705386‏
996		‎‡2 DNB\|1057115916‏
996		‎‡2 BNE\|XX4896738‏
996		‎‡2 CAOONL\|ncf10619152‏
996		‎‡2 ISNI\|0000000059972702‏
996		‎‡2 BNE\|XX1015529‏
996		‎‡2 LC\|no2002084669‏
996		‎‡2 BNF\|13750687‏
996		‎‡2 ISNI\|0000000502817302‏
996		‎‡2 BNE\|XX913499‏
996		‎‡2 BNCHL\|10000000000000000024314‏
996		‎‡2 PTBNP\|1185780‏
996		‎‡2 ISNI\|0000000109038855‏
996		‎‡2 BNE\|XX900235‏
996		‎‡2 RERO\|A022262974‏
996		‎‡2 BNE\|XX1007003‏
996		‎‡2 DNB\|129464732‏
996		‎‡2 DNB\|171893166‏
996		‎‡2 BNC\|981058523566806706‏
996		‎‡2 LC\|no2002019393‏
996		‎‡2 BNCHL\|10000000000000000009565‏
996		‎‡2 ISNI\|0000000119047907‏
996		‎‡2 SUDOC\|253992206‏
996		‎‡2 SUDOC\|069811253‏
996		‎‡2 NTA\|314860355‏
996		‎‡2 ISNI\|000000004884828X‏
996		‎‡2 BNE\|XX1554339‏
996		‎‡2 DNB\|1017066728‏
996		‎‡2 BNE\|XX6094744‏
996		‎‡2 PTBNP\|1609772‏
996		‎‡2 BNE\|XX1038381‏
996		‎‡2 BNE\|XX5129849‏
996		‎‡2 SUDOC\|189490942‏
996		‎‡2 BNE\|XX1646039‏
996		‎‡2 NTA\|314069704‏
996		‎‡2 ISNI\|0000000061025448‏
996		‎‡2 DNB\|141517263‏
996		‎‡2 BNE\|XX979855‏
996		‎‡2 LC\|n 2007072265‏
996		‎‡2 DNB\|1057436631‏
996		‎‡2 BNE\|XX824179‏
996		‎‡2 DNB\|105647808X‏
996		‎‡2 BNC\|981058513630106706‏
996		‎‡2 PTBNP\|216734‏
996		‎‡2 PTBNP\|1629625‏
996		‎‡2 NUKAT\|n 2005008467‏
996		‎‡2 NTA\|069545286‏
996		‎‡2 RERO\|A006481039‏
996		‎‡2 ISNI\|000000039930759X‏
996		‎‡2 BNE\|XX5469023‏
996		‎‡2 LC\|n 2010037378‏
996		‎‡2 ISNI\|0000000108158978‏
996		‎‡2 ISNI\|0000000059761163‏
996		‎‡2 ISNI\|0000000059216157‏
996		‎‡2 BNC\|981058515172106706‏
996		‎‡2 DNB\|1250428769‏
996		‎‡2 ISNI\|0000000068502243‏
996		‎‡2 LC\|no2017116271‏
996		‎‡2 BNE\|XX5525752‏
996		‎‡2 BNC\|981060555933106706‏
996		‎‡2 RERO\|A003227668‏
996		‎‡2 ISNI\|0000000116466786‏
996		‎‡2 ISNI\|0000000448737327‏
996		‎‡2 PTBNP\|1262132‏
996		‎‡2 LC\|n 97075963‏
996		‎‡2 ISNI\|0000000079716693‏
996		‎‡2 PTBNP\|1876546‏
996		‎‡2 BNE\|XX6474216‏
996		‎‡2 B2Q\|0001096483‏
996		‎‡2 LC\|n 80098391‏
996		‎‡2 BNF\|12245615‏
996		‎‡2 BNE\|XX933019‏
996		‎‡2 BNE\|XX6208889‏
996		‎‡2 DNB\|171834054‏
996		‎‡2 ISNI\|0000000060960370‏
996		‎‡2 NII\|DA15102285‏
996		‎‡2 PTBNP\|239765‏
996		‎‡2 CAOONL\|ncf11338767‏
996		‎‡2 ISNI\|0000000028490188‏
996		‎‡2 ISNI\|0000000107188462‏
996		‎‡2 LC\|nb2010023617‏
996		‎‡2 PTBNP\|1711587‏
996		‎‡2 LC\|n 2022183985‏
996		‎‡2 ISNI\|0000000069919235‏
996		‎‡2 BNE\|XX4738825‏
996		‎‡2 BNC\|981058607961606706‏
997		‎‡a 0 0 lived 0 0‏ ‎‡9 1‏

VIAF

Virtual International Authority File

Search